We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 322

HHS Proposes Disclosure of Drug Prices in TV Advertising, But Fight Over Authority On the Horizon
  • Arent Fox LLP
  • USA
  • October 29 2018

The Department of Health and Human Services (HHS) has issued a proposed rule (PR) which would require any television advertisement for a drug or


FDA Warns Against Sales Representative’s “False and Misleading” Oral Statements Regarding Prescription Medicine
  • Drinker Biddle & Reath LLP
  • USA
  • October 25 2018

The U.S. Food and Drug Administration’s Office of Prescription Drug Promotion (OPDP) sent an untitled letter to Eisai Inc. on October 11, 2018, based


Seventh Circuit Not Moooved by False Advertising Appeal
  • Baker & Hostetler LLP
  • USA
  • July 9 2018

Back in 2017, Arla Foods launched a series of 30-second TV spots as part of a $30 million campaign to expand


Coming soon from FDA? Streamlined safety information in prescription drug television ads
  • DLA Piper
  • USA
  • September 7 2017

Most people are by now familiar with prescription drug TV ads that provide lengthy (and often confusing) laundry-list descriptions of


ASA Adjudications Snapshot - March and April 2017
  • CMS Cameron McKenna Nabarro Olswang LLP
  • United Kingdom
  • May 26 2017

This summary provides a selection of March and April’s most interesting ASA adjudications and highlights the key issues considered in those rulings


NAD Consumer Protection in Retail: Weekly Roundup
  • Hunton Andrews Kurth LLP
  • USA
  • August 4 2016

The National Advertising Division (“NAD”) was busy this past week. The organization recommended that several companies modify or discontinue claims


Biosimilar applicants must provide notice of commercial marketing
  • Fanelli Haag
  • USA
  • July 19 2016

In a recent case involving Apotex’s proposed biosimilar product to Amgen’s Neulasta (pegfilgrastim). Amgen sought a preliminary injunction to


En Banc: Federal Circuit Provides Guidance on Application of On-Sale Bar to Contract Manufacturers
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • July 13 2016

Pharmaceutical and biotech companies breathed a sigh of relief Monday when the Federal Circuit unanimously ruled in a precedential opinion that the


CARU stresses out over claims for Spa product
  • Manatt Phelps & Phillips LLP
  • USA
  • June 17 2015

The Children’s Advertising Review Unit (CARU) was stressed out over implied claims made by The Maya Group for its Orbeez Body Spa. The product


Biomedical component-supplier immunity fulfills congressional intent
  • Weil Gotshal & Manges LLP
  • USA
  • September 8 2014

As you've probably noticed from the nigh-inescapable television commercials for plaintiff's law firms, controversy over pelvic mesh inserts, which